Jeong, H., Shin, J., Jeong, J., Kim, K., Hong, S., Kim, Y., . . . Yoo, C. (2021). Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: Single-arm phase II study. ESMO Open.

Jeong, H., J. Shin, J.H Jeong, K.-p Kim, S.-M Hong, Y.-i Kim, J.-S Ryu, B.-Y Ryoo, και C. Yoo. "Capecitabine Plus Temozolomide in Patients With Grade 3 Unresectable or Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms With Ki-67 Index <55%: Single-arm Phase II Study." ESMO Open 2021.

Jeong, H., et al. "Capecitabine Plus Temozolomide in Patients With Grade 3 Unresectable or Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms With Ki-67 Index <55%: Single-arm Phase II Study." ESMO Open 2021.